NASDAQ:TPST Tempest Therapeutics - TPST Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tempest Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.40 +0.09 (+6.87%) (As of 03/23/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.36▼$1.4350-Day Range$1.14▼$2.0452-Week Range$1.06▼$4.55Volume12,757 shsAverage Volume16,015 shsMarket Capitalization$14.73 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Tempest Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,066.7% Upside$16.33 Price TargetShort InterestHealthy0.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.44Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($3.25) to ($2.84) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.87 out of 5 starsMedical Sector691st out of 989 stocksPharmaceutical Preparations Industry330th out of 480 stocks 3.5 Analyst's Opinion Consensus RatingTempest Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.33, Tempest Therapeutics has a forecasted upside of 1,066.7% from its current price of $1.40.Amount of Analyst CoverageTempest Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.40% of the float of Tempest Therapeutics has been sold short.Short Interest Ratio / Days to CoverTempest Therapeutics has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tempest Therapeutics has recently increased by 17.86%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTempest Therapeutics does not currently pay a dividend.Dividend GrowthTempest Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TPST. Previous Next 0.9 News and Social Media Coverage News SentimentTempest Therapeutics has a news sentiment score of -0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Tempest Therapeutics this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tempest Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.14% of the stock of Tempest Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.32% of the stock of Tempest Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Tempest Therapeutics are expected to grow in the coming year, from ($3.25) to ($2.84) per share.Price to Book Value per Share RatioTempest Therapeutics has a P/B Ratio of 0.27. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tempest Therapeutics (NASDAQ:TPST) StockTempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.Read More Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Stock News HeadlinesMarch 23, 2023 | finanznachrichten.deTempest Therapeutics: Tempest Reports Year End 2022 Financial Results and Provides Business UpdateMarch 22, 2023 | finance.yahoo.comTempest Reports Year End 2022 Financial Results and Provides Business UpdateMarch 24, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. March 22, 2023 | finance.yahoo.comTempest Reports Year End 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | finance.yahoo.comTempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific MeetingMarch 15, 2023 | finance.yahoo.comTempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific MeetingMarch 15, 2023 | americanbankingnews.comTempest Therapeutics, Inc. (NASDAQ:TPST) Short Interest UpdateMarch 14, 2023 | finance.yahoo.comTempest to Present New Translational and Preclinical Data at the 2023 AACR Annual MeetingMarch 24, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. December 5, 2022 | finance.yahoo.comBears are Losing Control Over Tempest Therapeutics, Inc. (TPST), Here's Why It's a 'Buy' NowNovember 22, 2022 | finance.yahoo.comTempest to Present at the Piper Sandler 34th Annual Healthcare ConferenceNovember 10, 2022 | finance.yahoo.comTempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with CancerNovember 8, 2022 | finance.yahoo.comTempest Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 2, 2022 | finance.yahoo.comTempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual MeetingSeptember 15, 2022 | msn.com6KMPH, DDI : Benzinga's Top Ratings Upgrades, Downgrades For...September 7, 2022 | finance.yahoo.comTempest to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022 | finance.yahoo.comTempest to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 17, 2022 | seekingalpha.comTempest Therapeutics GAAP EPS of -$0.79August 17, 2022 | investing.comTempest Therapeutics, Inc. Tops Q2 EPS by 13cAugust 15, 2022 | finance.yahoo.comTempest Reports Second Quarter 2022 Financial Results and Provides Business UpdateJuly 19, 2022 | seekingalpha.comTPST Tempest Therapeutics, Inc.July 7, 2022 | benzinga.comTempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus ConferenceJune 9, 2022 | finance.yahoo.comTempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial GuidanceJune 6, 2022 | finance.yahoo.comTempest to Present at the Jefferies Healthcare ConferenceMay 26, 2022 | finance.yahoo.comTempest Reports Positive TPST-1120 Clinical Data from Phase 1 Trial in Patients with Advanced Solid Tumors at 2022 ASCO Annual MeetingMay 13, 2022 | seekingalpha.comTempest Therapeutics GAAP EPS of -$1.18 misses by $0.06May 13, 2022 | finance.yahoo.comTempest Reports First Quarter 2022 Financial Results and Provides Corporate HighlightsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TPST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TPST Company Calendar Last Earnings11/10/2021Today3/23/2023Next Earnings (Estimated)5/12/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TPST CUSIPN/A CIK1544227 Webwww.millendo.com Phone(415) 798-8589FaxN/AEmployees14Year Founded2012Price Target and Rating Average Stock Price Forecast$16.33 High Stock Price Forecast$35.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+547.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,300,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.15% Return on Assets-50.07% Debt Debt-to-Equity Ratio0.44 Current Ratio2.50 Quick Ratio2.50 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.23 per share Price / Book0.27Miscellaneous Outstanding Shares10,520,000Free Float9,976,000Market Cap$14.62 million OptionableNot Optionable Beta0.87 Social Links Key ExecutivesStephen R. BradyChief Executive Officer & DirectorThomas W. DubenskyPresident & DirectorSam WhitingChief Medical Officer & Executive Vice PresidentDarrin BombaVice President-Clinical OperationsAnne MoonSenior Vice PresidentKey CompetitorsIndaptus TherapeuticsNASDAQ:INDPChembio DiagnosticsNASDAQ:CEMIRedHill BiopharmaNASDAQ:RDHLUniverse PharmaceuticalsNYSE:UPCHumanigenNASDAQ:HGENView All CompetitorsInsidersThomas WoiwodeBought 2,118,644 shares on 4/29/2022Total: $5.00 M ($2.36/share)View All Insider Transactions TPST Stock - Frequently Asked Questions Should I buy or sell Tempest Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TPST shares. View TPST analyst ratings or view top-rated stocks. What is Tempest Therapeutics' stock price forecast for 2023? 4 brokers have issued 12 month target prices for Tempest Therapeutics' stock. Their TPST share price forecasts range from $6.00 to $35.00. On average, they anticipate the company's share price to reach $16.33 in the next twelve months. This suggests a possible upside of 1,075.1% from the stock's current price. View analysts price targets for TPST or view top-rated stocks among Wall Street analysts. How have TPST shares performed in 2023? Tempest Therapeutics' stock was trading at $1.15 at the start of the year. Since then, TPST shares have increased by 20.9% and is now trading at $1.39. View the best growth stocks for 2023 here. Are investors shorting Tempest Therapeutics? Tempest Therapeutics saw a increase in short interest in February. As of February 28th, there was short interest totaling 16,500 shares, an increase of 17.9% from the February 13th total of 14,000 shares. Based on an average daily volume of 16,100 shares, the short-interest ratio is currently 1.0 days. Approximately 0.4% of the company's stock are short sold. View Tempest Therapeutics' Short Interest. When is Tempest Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 12th 2023. View our TPST earnings forecast. How were Tempest Therapeutics' earnings last quarter? Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.21) earnings per share for the quarter, missing analysts' consensus estimates of ($1.05) by $0.16. When did Tempest Therapeutics' stock split? Shares of Tempest Therapeutics reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 28th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Tempest Therapeutics' stock symbol? Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST." Who are Tempest Therapeutics' major shareholders? Tempest Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Thomas W Dubensky and Thomas Woiwode. View institutional ownership trends. How do I buy shares of Tempest Therapeutics? Shares of TPST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tempest Therapeutics' stock price today? One share of TPST stock can currently be purchased for approximately $1.39. How much money does Tempest Therapeutics make? Tempest Therapeutics (NASDAQ:TPST) has a market capitalization of $14.62 million. How can I contact Tempest Therapeutics? Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The official website for the company is www.millendo.com. The company can be reached via phone at (415) 798-8589 or via email at stephanie@sternir.com. This page (NASDAQ:TPST) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.